Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

The steady-state pharmacokinetics and pharmacodynamics of two oral doses of lopinavir-ritonavir (lopinavir/r; 400/100 and 533/133 mg) twice daily (BID) when dosed in combination with efavirenz, plus two nucleoside reverse transcriptase inhibitors, were assessed in a phase II, open-label, randomized,...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	Antimicrob Agents Chemother
Autori principali:	Hsu, Ann, Isaacson, Jeffrey, Brun, Scott, Bernstein, Barry, Lam, Wayne, Bertz, Richard, Foit, Cheryl, Rynkiewicz, Karen, Richards, Bruce, King, Martin, Rode, Richard, Kempf, Dale J., Granneman, G. Richard, Sun, Eugene
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 2003
Soggetti:	Antiviral Agents
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC148953/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12499212/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.1.350-359.2003
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!